Journal
CELLULAR SIGNALLING
Volume 60, Issue -, Pages 65-80Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.cellsig.2019.04.007
Keywords
Cholesterol; Apolipoproteins; Lysophospholipids; Eicosanoids; Lipid transporters; Lung fibrosis
Categories
Funding
- German Research Foundation [DFG: WY119/1-3, SFB 815, SFB 1039, SFB 1177, 259130777, SCHA 1082/6-1]
- Else Kroner-Fresenius-Foundation
- LUNGENFIBR02E(R)e.V. Foundation
- German Center for Lung Research
Ask authors/readers for more resources
Idiopathic pulmonary fibrosis (IPF) is characterized by progressive extracellular matrix deposition in the lung parenchyma leading to the destruction of lung structure, respiratory failure and premature death. Recent studies revealed that the pathogenesis of IPF is associated with alterations in the synthesis and the activity of lipids, lipid regulating proteins and cell membrane lipid transporters and receptors in different lung cells. Furthermore, deregulated lipid metabolism was found to contribute to the profibrotic phenotypes of lung fibroblasts and alveolar epithelial cells. Consequently, several pharmacological agents, targeting lipids, lipid mediators, and lipoprotein receptors, was successfully tested in the animal models of lung fibrosis and entered early phase clinical trials. In this review, we highlight new therapeutic options to counteract disturbed lipid hemostasis in the maladaptive lung remodeling.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available